secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-133784
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029
--------------------------------------------------------------------------------

- Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).
- Net loss $37.4M ($0.32 per share) vs $34.1M ($0.30 per share) in Q1 2023; R&D expenses $35.4M, SG&A $29.5M.
- Reaffirms FY2024 guidance: total revenue $140-160M; XPOVIO net product revenue $100-120M; R&D+SG&A $260-280M.
- Completed refinancing: extended majority of debt maturities to 2028/2029 and amended HCRx royalty, reducing royalty rate from 12.5% to 7.0%.
- Cash, equivalents, restricted cash and investments $149.3M as of March 31, 2024; cash runway expected into end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/0001193125-24-133784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/d809399d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-133784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer